All In Biotech

Drug Trial Radar · NCT07793409

A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)

An Extension Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig, Including Inhaled Corticosteroid Withdrawal, in Adults With Chronic Obstructive Pulmonary Disease (COPD) Who Completed Studies EFC18243 or EFC18244

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. Randomized with 1,508 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

1,508

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Jul 23, 2031

Study completion Jul 23, 2031

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, Phase 3, long-term safety extension study including participants of previous lunsekimig clinical trials with inadequately controlled chronic obstructive pulmonary disease (COPD ) characterized by an eosinophilic phenotype. The purpose of the LTS 18211 study is to characterize the long-term safety and efficacy of lunsekimig in adults with COPD who completed studies EFC18243 or EFC18244 in the main study, and to assess the impact of inhaled corticosteroids (ICS ) withdrawal in the ICS withdrawal sub-study. The study duration will be up to 100 weeks, including the following components: * Baseline Visit (Visit 1 / Week 0) will coincide with the End-of-Intervention visit from the parent study (EFC18243 or EFC18244) if possible * Treatment duration of up to 96 weeks * Safety follow-up period of approximately 4 weeks * The number of visits will be 26

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • LunsekimigDrug

    * Pharmaceutical form: Solution for injection in prefilled syringe * Route of administration: Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Exposure-adjusted incidence rate of treatment-emergent adverse events (TEAE), including adverse events of special interest (AESI ) and serious adverse events (SAE)Time frame: Study baseline to Week 100
  2. ICS withdrawal sub-study: Change from Week 12 (end of run-in period) to Week 36 in pre-Bronchodilator Forced Expiratory Volume in 1 second (pre-BD FEV1)Time frame: From Week 12 to Week 36

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • Newport Native MD- Site Number : 8403003

    Newport Beach, California

  • Helix Biomedics- Site Number : 8403065

    Boynton Beach, Florida

  • Innovations Biotech- Site Number : 8404019

    Miami, Florida

  • Deluxe Health Center- Site Number : 8403010

    Miami Lakes, Florida

  • Clinical Research Trials of Florida- Site Number : 8403011

    Tampa, Florida

  • Private Practice - Dr. David Kavtaradze- Site Number : 8403006

    Cordele, Georgia

  • Investigational Site Number : 0324005

    Buenos Aires, Argentina

  • Investigational Site Number : 1243004

    Guelph, Ontario, Canada

  • Investigational Site Number : 1244050

    Saint-Charles-Borromée, Quebec, Canada

  • Investigational Site Number : 1244042

    Victoriaville, Quebec, Canada

  • Investigational Site Number : 1523003

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1564021

    Huzhou, China

  • Investigational Site Number : 1564077

    Luoyang, China

  • Investigational Site Number : 1563011

    Xiangtan, China

  • Investigational Site Number : 8264017

    Rotherham, United Kingdom

  • Investigational Site Number : 8264013

    Chertsey, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.